The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors

Surgery Today

Volumn 43, Issue 10, 2013, Pages 1162-1167

  Yoshikawa, Kozo ^a   Shimada, Mitsuo ^a   Kurita, Nobuhiro ^a   Sato, Hirohiko ^a   Iwata, Takashi ^a   Morimoto, Shinya ^a   Miyatani, Tomohiko ^a   Kashihara, Hideya ^a   Takasu, Chie ^a   Matsumoto, Noriko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

GIST; PET CT

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CELL COUNT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; LABELING INDEX; LOW RISK POPULATION; MALE; MALIGNANT TRANSFORMATION; MAXIMUM STANDARDIZED UPTAKE VALUE; MITOSIS INDEX; OUTCOME ASSESSMENT; PREDICTION; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT;

ADULT; AGED; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884905143     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0411-6     Document Type: Article

References (28)

1. Kamiyama Y, Aihara R, Nakabayashi T. F-Fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005;29:1429-35.
2. Eliseberg B, Jonathanharris MS. Phase II trial of neoadjuvant/adjuvant imatinib metastatic/recurrent operable gastrointestinal stromal tumor (GIST). J Surg Oncol. 2009;99:42-7.
3. John O, Montemurro M, Victoria M. Early prediction of response to sunitinib after imatinib failure by F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2008;27:439-45.
4. Haesun C, Chuslip C, Silvan C. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9.
5. Clay H, Holdsworth D, Badawi B. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. 2007;189:324-30.
6. Patrick V, Valerie T, Klaus S. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. Abdom Imaging. 2009;11:23-6.
7. Isis G, Thuan V, Revathy I. The role of F-FDG PET in staging and early prediction ob response to therapy ob recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
8. Ronald P, DeMatteo J, Lisa S. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608-15.
9. Ando K, Sugiyama M, Zhao Y, Kojima A, Yamamoto H, Yamashita Y, et al. Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate. Surg Today. 2011;41:1290-3.
10. DeMatte RP, Maki RG, Samuel S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Aun Surg. 2007;245:347-52.
11. Wong NA, Young R, Malcomson RDG, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118-26.
12. Charles D, Cathryn R, Demetri DG, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase. J Clin Oncol. 2008;26:626-32.
13. Eisenberg BL, Jonathan H, Charles B. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST)-early results of RTOG 0132. J Surg Oncol. 2009;1:42-7.
14. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized Phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-5.
15. Fujimoto Y, Nakanishi Y, Yoshimura K. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39-48.
16. Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459-65.
17. Otsuka H, Terazawa K, Morita M. Is FDG-PET/CT useful for managing malignant pleural mesothelioma? J Med Invest. 2009;56:16-20.
18. Otsuka H, Morita N, Yamashita K. FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis. Ann Nucl Med. 2007;21:593-6.
19. Otsuka H, Morita N, Yamashita K. FDG-PET/CT for cancer management. J Med Invest. 2007;54:195-9.
20. Wong R, Young R, Malcomson D. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003;43:118-26.
21. Burkill GJ, Badran M, Al-Muderis O. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527-32.
22. Nishida T, Kumano S, Sugiura T. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR. 2003;180:185-9.
23. Demetri G. Identification and treatment of chemoresistant inoperable or meta-static GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571). Eur J Cancer. 2002;38:52-9.
24. Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
25. Valk PE. Pounds by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573-81.
26. Vitola JV, Delbeke D, Sandler MP. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21-6.
27. Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270-4.
28. Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST. J Gastric Cancer. 2011;11:173-9.